Abstracts tagged "giant cell arteritis and temporal arteritis"

Abstract Number: 2776 • 2018 ACR/ARHP Annual Meeting
Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis
Nicolò Pipitone¹, Francesco Muratore², Ione Tamagnini³, Alberto Cavazza⁴, Luca Cimino⁵, Luigi Boiardi², Giovanna Restuccia⁶, Martina Bonacini⁷, Stefania Croci⁷ and Carlo Salvarani⁸, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ³Pathology Unit, Department of Oncology, Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, ⁷Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁸Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To evaluate if interleukin-6 (IL-6) expression in the temporal artery biopsy (TAB) specimens may differentiate patients with giant cell arteritis (GCA) from those without.…
Abstract Number: 2782 • 2018 ACR/ARHP Annual Meeting
Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?
Mahjabeen Haq¹, Danielle Schwartz¹, Monica Weinberg¹, Jillian Cepeda¹, Erin Taub², Asha Patniak³ and Qingping Yao⁴, ¹Department of Medicine-Rheumatology, Allergy, and Immunology Division, Stony Brook University Hospital, stony brook, NY, ²Department of Medicine, Stony Brook University Hospital, stony brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Rheumatology, Allergy and Immunology, Stony Brook University Hospital, Stony Brook, NY
Background/Purpose: Giant cell arteritis (GCA) and Temporal arteritis (TA) is characterized by chronic granulomatous inflammation in medium and large-sized vessels. It affects 20 in 100,000…
Abstract Number: 2762 • 2018 ACR/ARHP Annual Meeting
A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort
Sarah H. Chung¹, Meredith B. Morcos¹ and Bernard Ng^1,2, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: TAB is currently considered the gold standard for the diagnosis of GCA. However, it is suspected that the sensitivity of TAB is limited by…
Abstract Number: 2769 • 2018 ACR/ARHP Annual Meeting
A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients
Ammar Haikal¹, Garth Fraga², Jason Springer¹ and Mehrdad Maz³, ¹Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, ²The University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS, ³Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Giant cell arteritis (GCA) is a systemic vasculitis of large and medium-sized arteries mostly reported in Caucasians (CCs) over 50 y.o. There is limited…
Abstract Number: 777 • 2017 ACR/ARHP Annual Meeting
Differences between Temporal Artery Biopsy-Positive and Biopsy-Negative Giant Cell Arteritis: A Comparative Cohort Study
Matthew J. Koster¹, Karthik Yeruva¹, Cynthia S. Crowson² and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in patients aged 50 years or older. The presence of cranial features and an…
Abstract Number: 1963 • 2015 ACR/ARHP Annual Meeting
Specialty of Provider Referring for Temporal Artery Biopsy Affects the Likelihood of Giant Cell Arteritis (GCA) Diagnosis
Lindsay Lally¹ and Robert F. Spiera², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, HSS, New York, NY
Background/Purpose: Presenting signs/symptoms of GCA can be nonspecific and patients can initially present to a spectrum of clinical specialties. While temporal artery biopsy (TAB) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].